Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports

BACKGROUND: Recurrent hepatocellular carcinoma (HCC) with inferior vena cava tumor thrombus is a great challenge for oncologists and has a poor prognosis. To date, the safety and efficacy of programmed cell death ligand 1 (PD-L1) inhibitors are still unknown. CASE SUMMARY: A 59-year-old male was ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shao-Ru, Yan, Qing, Lin, Hao-Ming, Shi, Guang-Zi, Cao, Yi, Zeng, Hong, Liu, Chao, Zhang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316958/
https://www.ncbi.nlm.nih.gov/pubmed/34368318
http://dx.doi.org/10.12998/wjcc.v9.i21.5988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316958/
https://www.ncbi.nlm.nih.gov/pubmed/34368318
http://dx.doi.org/10.12998/wjcc.v9.i21.5988

Ejemplares similares